Research Article
The Natural History of Biopsy-Negative Rejection after Heart Transplantation
Table 3
Characteristics of biopsy-negative rejection.
| | Characteristics | BNR cases () |
| | De novo antibody development posttransplant before BNR onset, % | 3/12 (25%) | | Donor-specific antibody, % | 1/3 (33%) | | LVEF % SD | | | At discharge of initial hospitalization for heart transplant | 61% 6% | | Last LVEF before BNR onset | 53% 6% | | At BNR presentation | 34% 10% | | Cases with 1st year BNR, % | 11/12 (92%) | | No treated rejection before BNR, % | 11/12 (92%)* | | Biopsy features before BNR () | | | Biopsy cellular rejection episodes (1A, 1B, or 1R), % | 25/106 (23%) | | Biopsy antibody-mediated rejection episodes (1), % | 1/106 (0.9%) | | Treatment | | | Require inotropes, % | 4/12 (16.7%) | | IV methylprednisolone followed by prednisone bolus and taper, % | 4/12 (33%) | | ATG, % | 3/12 (25%) | | IVIG, % | 3/12 (25%) | | Oral steroid treatment non-CHF cases, % | 7/12 (58%) | | Outcome | | | Cases with normalized LVEF, % | 7/12 (58%) | | Mean LVEF at recovery, LVEF % SD | 57% 6% | | Mean days to recovery, days SD | | | Negative (ACR 0R, AMR 0) biopsy result after treatment, % | 10/12 (83%) |
|
|
The only case that represented the patient who had two BNRs during followup.
|
